Leerink Partnrs Has Negative Outlook of Sanofi Q3 Earnings

Key Points

• Leerink Partners has downgraded Sanofi's Q3 EPS estimates for 2025, projecting earnings of $1.58 per share, down from $1.59, while the consensus full-year estimate remains at $4.36 per share.
• Sanofi reported Q2 earnings of $0.90 per share, missing analysts' expectations of $0.96 and showing a 7.0% decline in revenue year-over-year.
• Despite the negative outlook, several analysts maintain a positive view, with multiple upgrades to a "buy" rating, and an average price target of $62.67 for Sanofi shares.

Sanofi (NASDAQ:SNY - Free Report) - Research analysts at Leerink Partnrs cut their Q3 2025 EPS estimates for Sanofi in a note issued to investors on Tuesday, September 30th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn $1.58 per share for the quarter, down from their prior forecast of $1.59. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi's FY2025 earnings at $4.27 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts' consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same period in the prior year, the business posted $1.73 EPS. Sanofi's revenue for the quarter was down 7.0% on a year-over-year basis.

A number of other equities analysts also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. raised shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Guggenheim reaffirmed a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. Wall Street Zen raised shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, Morgan Stanley raised shares of Sanofi from an "equal weight" rating to an "overweight" rating and raised their price target for the company from $56.00 to $58.00 in a research report on Monday, September 8th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $62.67.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $47.20 on Wednesday. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The company has a 50 day simple moving average of $48.19 and a two-hundred day simple moving average of $50.21. The company has a market capitalization of $115.90 billion, a price-to-earnings ratio of 11.35, a P/E/G ratio of 1.08 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.94 and a current ratio of 1.27.

Institutional Trading of Sanofi

Institutional investors and hedge funds have recently modified their holdings of the company. Cardinal Capital Management increased its holdings in Sanofi by 0.3% in the 1st quarter. Cardinal Capital Management now owns 69,004 shares of the company's stock valued at $3,827,000 after acquiring an additional 199 shares during the last quarter. Gradient Investments LLC increased its holdings in shares of Sanofi by 2.1% in the 1st quarter. Gradient Investments LLC now owns 9,764 shares of the company's stock worth $542,000 after buying an additional 200 shares during the last quarter. Perigon Wealth Management LLC increased its holdings in shares of Sanofi by 3.1% in the 1st quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company's stock worth $367,000 after buying an additional 201 shares during the last quarter. Capital Analysts LLC increased its holdings in shares of Sanofi by 14.0% in the 1st quarter. Capital Analysts LLC now owns 1,664 shares of the company's stock worth $92,000 after buying an additional 204 shares during the last quarter. Finally, Thomasville National Bank increased its holdings in shares of Sanofi by 0.3% in the 2nd quarter. Thomasville National Bank now owns 80,440 shares of the company's stock worth $3,886,000 after buying an additional 211 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.